Evidence map›Paper›PMID 31729388›Full record

ArticleNature communications2019

Enantiodivergence by minimal modification of an acyclic chiral secondary aminocatalyst.

Jun Dai, Zhuang Wang, Yuhua Deng, Lei Zhu, Fangzhi Peng, Yu Lan, Zhihui Shao

Abstract read
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Flipping the Card With Enantiodivergent Organocatalysis.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Construction of chiral α-Chemical science · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jun DaiKey Laboratory of Medicinal Chemistry for Natural Resource, School of Chemical Science and Technology, and State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, Yunnan University, 650091, Kunming, China.
Zhuang WangKey Laboratory of Medicinal Chemistry for Natural Resource, School of Chemical Science and Technology, and State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, Yunnan University, 650091, Kunming, China.
Yuhua DengKey Laboratory of Medicinal Chemistry for Natural Resource, School of Chemical Science and Technology, and State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, Yunnan University, 650091, Kunming, China.
Lei ZhuSchool of Chemistry and Chemical Engineering, Chongqing Key Laboratory of Theoretical and Computational Chemistry, Chongqing University, 400030, Chongqing, China.
Fangzhi PengKey Laboratory of Medicinal Chemistry for Natural Resource, School of Chemical Science and Technology, and State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, Yunnan University, 650091, Kunming, China.
Yu LanSchool of Chemistry and Chemical Engineering, Chongqing Key Laboratory of Theoretical and Computational Chemistry, Chongqing University, 400030, Chongqing, China. lanyu@cqu.edu.cn.
Zhihui ShaoKey Laboratory of Medicinal Chemistry for Natural Resource, School of Chemical Science and Technology, and State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan, Yunnan University, 650091, Kunming, China. zhihui_shao@hotmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of enantiodivergent catalysis for the preparation of both enantiomers of a chiral compound is of importance in pharmaceutical and bioorganic chemistry. With the design of a class of reactive and stereoselective organocatalysts, acyclic chiral secondary amines, a method for achieving the enantiodivergence is developed simply by changing the secondary N-i-Bu- to N-Me-group within the catalyst architecture while maintaining the same absolute configuration of the catalysts, which modulates the catalyst conformation. This catalyst-controlled enantiodivergent method not only enables challenging asymmetric transformations to occur in an enantiodivergent manner but also features a high level of stereocontrol and broad scope that is demonstrated in eight different reactions (90 examples), all delivering both enantiomers of a range of structurally diverse products including hitherto less accessible, yet important, compounds in good yields with high stereoselectivities.

Identifiers

PMID31729388
PMCPMC6858435

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.